Biosimilars could reduce pharmacy costs

With changing pharmacy costs and a rising use of specialty drugs, it is no surprise that drug prices are a main topic of discussion these days. Biologics, a class of specialty drugs, are crucial for treating chronic conditions, and represent a hefty portion of pharmaceutical spending in the U.S.

Yet, biosimilars, their more affordable counterparts, remain underutilized and could significantly reduce pharmacy costs. Why the gap in prescribing biosimilars?

Key factors include adoption barriers and the need for accurate information among prescribers. Check out this article on the potential of biosimilars to curb costs and enhance access to vital treatments, and how employers can help.